Neoadjuvant chemoradiotherapy plus sintilimab in pMMR/MSS rectal cancer patients with PD-L1 TPS ≥ 1% or CPS ≥ 1: an open-label, prospective, phase II study by Zhenlin Hou, Leen Liao, Weiwei Xiao, Qiaoqi Sui, Kai Han, Binyi Xiao, Yuan Li, Weijian Mei, Jiehai Yu, Zhigang Hong, Qichen Chen, Ruyue Song, Dandan Li, Xiaoshi Zhang, Qiaoxuan Wang, Zhizhong Pan, Wu Jiang, Peirong Ding

Get full text